Nuformix plc
Research Nuformix plc (NFX) on Bullrun: market cap GBX 430.61M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNFX
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 430.61M
- Financial periodFY2025
- RevenueGBP 0
- Net income-GBP 652.59K
- Free cash flow-GBP 614.61K
Valuation Snapshot
latest market cap is GBX 430.61M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 0 | -GBP 652.59K | -GBP 614.61K | n/a | 0 | GBP 97.55K | n/a | GBP 754.94K |
| FY2024 | GBP 0 | -GBP 3.64M | -GBP 331.88K | n/a | 0 | GBP 20.21K | n/a | GBP 715.57K |
| FY2023 | n/a | n/a | n/a | n/a | 0 | n/a | n/a | n/a |
| FY2022 | GBP 50.00K | -GBP 1.11M | -GBP 1.35M | 96.6% | 0 | GBP 464.10K | n/a | GBP 4.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | GBX 430.61M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Nuformix plc
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nuformix plc's market cap?
Nuformix plc's market capitalization is GBX 430.61M.
What does Nuformix plc do?
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NXP001 for oncology indications.